28 results about "Cell Surface Proteins" patented technology

The invention provides a three-specificity immune cell adapter-cytokine fusion protein for malignant tumor immunotherapy as well as a preparation method and application of the three-specificity immune cell adapter-cytokine fusion protein. The fusion protein comprises a first binding domain, a second binding domain and a cytokine structural domain which are covalently linked to form a single polypeptide chain or polypeptide compound. The first binding domain is specifically bound with a tumor associated antigen, and the target spot of the first binding domain comprises but is not limited to KK-LC-1, MSLN, HER2, Claudin18.2, Claudin6 and PSMA; the second binding domain is specifically bound with a CD3 protein complex on the surface of the T cell; the cytokine domain is IL2, IL15, IL12, IL21 or a functional variant thereof. The invention also relates to a nucleic acid molecule for coding the fusion protein, an expression vector and application thereof. The fusion protein can be used for immunotherapy of malignant tumors such as colon cancer, gastric cancer, breast cancer, liver cancer, lung cancer and cervical cancer, and has a good application prospect. The invention effectively solves the problems of insufficient T cell activation and limited killing in solid tumor immunotherapy in the prior art.

A rapid detection method for cytotoxic T cells in peripheral blood. The method enables rapid identification of cytotoxic T cells in peripheral blood by detecting the expression of T-cell surface protein CX3CR1, or CX3CR1 and GPR56. The detection method is rapid in operation, does not involve cell fixation and permeabilization, and does not affect cell activity.

The application relates to preparation and application of anti-CD38 rabbit recombinant monoclonal antibodies, the obtained antibodies have good specificity, most importantly, the antibodies have high affinity and can recognize natural cell surface CD38 proteins, and can be used for flow, ELISA and immunohistochemical detection applications.

The present disclosure provides methods and compositions for using a novel class of glycan conjugates for modulating cell surface proteins and receptor complexes that can be used to engage signaling pathways within desired cell types. Such defined cell-targeting bioactive glycoligands are directed to cell engagement and activation in therapeutic applications.

Genetically engineered cells (e.g., HSPCs or T cells), such as hematopoietic stem cells, having one or more genetically edited genes of cell-surface proteins, and therapeutic uses thereof, either alone or in combination with immune therapy that targets the cell-surface protein(s).

The application provides a method for separating and purifying cell surface proteins and application thereof. The method comprises the following steps: culturing cells to be separated, adding an azide solution to the cells for incubation, then adding a Tris-HCl buffer to terminate the reaction, so as to label the cell surface proteins with azides; then adding a TNTE buffer and a protease inhibitor to lyse the cells, centrifuging to obtain cell lysates labeled with azides; incubating the cell lysates labeled with azides with phosphine-biotin-streptavidin magnetic beads, so as to enrich the cell surface proteins labeled with azides, and obtain magnetic beads containing the cell surface proteins. The method can effectively separate the cell surface proteins, has low background, high efficiency and good repeatability, and can be applied to quantitative analysis of cell surface proteomes.

A transkingdom platform for the delivery of therapeutics to target cells. The system maintains the export and uptake functions of Inv while modifying its targeting away from β1 integrin to other proteins expressed on the surface of target eukaryotic cells (i.e., a cell surface protein) or chemical moieties (i.e., a cell surface chemical moiety) expressed on the surface of a target eukaryotic cell by replacing D4 and D5 of Inv with a binding domain from a heterologous protein via genetic engineering. These heterologous proteins could be derived from bacterial, fungal, animal, or viral genomes. This engineering would result in the construction of a chimeric Inv protein in which D1-D3 (i.e., the non-binding domains) are fused in frame to an alternative binding domain derived from a heterologous protein. The alternative binding domain would interact with a different cell surface protein or chemical moiety, which can in some instances be referred to as a receptor, on the surface on the surface of a eukaryotic cell, thereby allowing specific targeting to cells independent of Inv's intrinsic β1 integrin binding.

Therapeutic compounds for inhibiting and reducing expression of cell surface proteins, and methods of treating cancer, inflammation, and diabetes using the same.

Tumor cell identification is of great importance for cancer diagnosis, which is mainly focused on the identification of cell surface proteins. In this work, we demonstrate that high specificity can be achieved by integrating cell surface proteins and dual miRNAs to design sensors. DNA tetrahedron sensors are designed by assembling an aptamer, two miRNA complementary sequences and multiple complementary strands. The aptamer is specific to the membrane protein of tumor cells. The two complementary miRNA sequences are used to construct an AND logic signal output in response to the dual miRNAs in cells. Only when the membrane protein and the dual miRNAs exist simultaneously, the sensor can work in cells with high specificity. By imaging different types of membrane proteins and cancer cells with different expression of dual miRNAs, the DNA tetrahedron sensor has excellent accuracy in imaging analysis of target tumor cells.

Tumors use a variety of mechanisms to avoid the host's anti-tumor immune response. Humoral immune suppression is one of the mechanisms. Tumors produce circulating factors that can suppress antibody or complement-mediated immune responses to enhance their own survival. Mesothelin is a cell surface protein that is overexpressed by several cancer types that are associated with a microenvironment that exhibits immune suppression. Anti-mesothelin antibodies often suffer from such immune suppression microenvironments. However, an alternatively formatted anti-mesothelin antibody is effective in killing mesothelin-expressing cancers, independent of the tumor microenvironment immune status.

The present disclosure relates to heterobifunctional molecules, referred to as cytotoxicity targeting chimeras (CyTaCs) or antibody recruiting molecules (ARMs) that are able to simultaneously bind a target cell-surface protein as well as an exogenous antibody protein. The present disclosure also relates to agents capable of binding to a receptor on a surface of a pathogenic cell and inducing the depletion of the pathogenic cell in a subject for use in the treatment of cancer, inflammatory diseases, autoimmune diseases, viral infection, or bacterial infection.

The present invention provides compositions and methods related to the cell surface protein CRB1 for the treatment of retinopathies in a subject. In particular, isolated polynucleotides and recombinant vectors encoding a particular isoform called Crumbs 1-B (CRB1-B) are provided. The CRB1-B encoding polynucleotides may be operably linked to a heterologous promoter capable of expressing the isoform in a retinal cell. Kits employing such compositions are also provided.

Disclosed herein are methods, systems, and compositions for enhancing the effectiveness of β-cell (Beta-cell)-based therapies. Also disclosed herein are methods, systems, and compositions related to identifying, sorting and separating heterogeneous populations of stem cell-derived pancreatic β-cells (sBCs) into more useful and functionally homogeneous cell populations. In many embodiments, the most mature and functional of the sBCs are identified and live-sorted using the cell surface protein Ectonucleoside Triphosphate Diphosphohydrolase-3 (ENTP3), which is also referred to as CD39L3. The presently disclosed methods, systems, and compositions are useful for cell therapies, for example replacement therapy. In many embodiments the disclosed systems, methods, and compositions are useful in treatments for diabetes. In some embodiments, the disclosed methods, systems, and compositions may be useful in treating, preventing, and / or curing diabetes, for example type-1 diabetes.

The application relates to preparation and application of anti-CD22 rabbit recombinant monoclonal antibodies. The obtained antibodies have good specificity, and most importantly, the antibodies have high affinity and can recognize natural cell surface CD22 proteins, and can be used for flow and ELISA detection applications.

This disclosure relates to immunogenic compositions comprising Borrelia cell surface protein A (OspA) antigen or RNA polynucleotide encoding the OspA antigen, and an adjuvant. In some embodiments, the immunogenic compositions are suitable for stimulating an immune response to Borrelia in a subject. This disclosure also relates to kits of immunogenic compositions, their use, and methods of using them.

The present disclosure relates to methods of treating leukemia using a heterobifunctional molecule, referred to as a cytotoxicity targeting chimera (CyTaC) or antibody recruiting molecule (ARM), that is able to simultaneously bind a target cell-surface protein as well as an exogenous antibody protein.

Genetically engineered cells such as hematopoietic stem cells (e.g., HSPCs or T cells) with one or more gene-edited genes for cell surface proteins, and their therapeutic uses either alone or in combination with immunotherapies targeting the cell surface protein(s).

The invention relates to a polypeptide targeting SGCA and application of the polypeptide in cardiac specific drug delivery. Specifically, the invention relates to a polypeptide capable of being specifically combined with myocardial cell surface SGCA protein, a coding nucleic acid of the polypeptide, and a polypeptide conjugate containing the targeting peptide. The invention further relates to application of the SGCA targeting peptide in preparation of drugs or reagents for detecting, preventing, relieving or treating cardiovascular diseases, for example, the SGCA targeting peptide can be coupled with the drugs or the detection reagents to form a targeting delivery system, and therefore efficient and specific delivery of the drugs or the detection reagents to myocardial cells is achieved. The targeting peptide disclosed by the invention has excellent heart targeting property and cell internalization capability, and meanwhile, the treatment effect of the medicine can be remarkably improved, and systemic toxic and side effects can be reduced.

The present invention relates to bispecific antigen-binding polypeptides that may be used to remove unwanted agents, such as viruses or toxins, from the body and target them for degradation. The bispecific antigen-binding polypeptides of the invention have a first antigen-binding domain that binds an extracellular molecule and a second antigen-binding domain that binds to a cell surface protein, whereby the cell surface protein mediates internalisation of the bound complex. The invention also relates to pharmaceutical compositions comprising the bispecific antigen-binding poly peptides, and to methods of targeting an extracellular molecule for cellular internalisation and degradation via the lysosomal pathway.

The application provides a single cell analysis chip combining a carbon-based field effect transistor and microfluidics, comprising a plurality of single cell capture units; wherein the single cell capture unit comprises a sensing unit and a PDMS microfluidic channel unit arranged correspondingly to the sensing unit; the sensing unit is a carbon-based field effect transistor, and the PDMS microfluidic channel unit comprises a circular capture trap chamber vertically and directly above a sensing area of the carbon-based field effect transistor and a narrow channel; a first end of the circular capture trap chamber is connected with a first end of a first main channel, a second end of the circular capture trap chamber is connected with a first end of a second main channel through the narrow channel, and the first main channel and the second main channel are connected through an arc-shaped side channel; after cells are captured through the narrow channel, subsequent cells can flow into the next PDMS microfluidic channel unit through the arc-shaped side channel. The chip can separate and capture single cells, and achieve the purpose of detecting the surface proteins of single cells.

A therapeutic compound for inhibiting and reducing the expression of cell surface proteins, and a method for treating cancer, inflammation, and diabetes using the therapeutic compound. The therapeutic compound comprises a conjugate configured to bind to a second protein expressed on the surface of a target cell, the conjugate comprising a first protein coupled to an API, the conjugate configured to bind to the second protein expressed on the surface of the target cell in such a manner that it inhibits the activity of the second protein, and the conjugate is further configured to be internally transported by the target cell once it has bound to the second protein expressed on the surface of the target cell.

The present disclosure provides a method of identifying lung cancer in a subject in need there of comprising detecting circulating genetically abnormal cells (CGAC) in a sample comprising a population of cells. CGACs can be identified and classified according chromosomal hybridization patterns detected via fluorescent in situ hybridization (FISH). The identification of lung cancer can also comprise the evaluation of at least one nuclear parameter in the CGAC and / or identifying the presence or absence of an intracellular or cell surface protein in the CGAC.

The invention relates to the technical field of biological medicine, in particular to a lung cancer cell surface immune checkpoint inhibitor specificity detection system, a construction method, a use method and application. The lung cancer cell surface immune checkpoint inhibitor specificity detection system comprises a sorting probe for sorting lung cancer cells from blood, a capture probe capable of capturing cell surface proteins, a detection probe with a magnetic separation function, and a glucometer for measuring released glucose, the sorting probe is a magnetic microsphere modified by double aptamers; the protein capture probe is ZIF-8 of which the surface is modified with a PD-L1 aptamer, and glucose is entrapped on the ZIF-8. The system provided by the invention does not relate to a certain specific nucleic acid sequence, can realize detection of various target objects only by simply replacing aptamers and complementary nucleic acid sequences on the capture probe and the detection probe, and has broad spectrum and universality.

Disclosed herein are compositions comprising immune-activating agents that bind the tumor cell surface in the absence of a tumor-targeting protein component. Described herein are methods and compositions for targeting a TLR or STING agonist to tumor cells and / or cells in the tumor microenvironment. It is hypothesized that the metabolic stress of tumor growth also produces an excess of unpaired cysteines on cell surface proteins relative to the rest of the body. Therefore, this chemistry can be used with compounds that would preferentially target unpaired cysteines on cell surface proteins.

Genetically engineered cells, such as hematopoietic stem cells (e.g., HSPCs), with one or more gene-edited genes for cell surface proteins, and their therapeutic uses, either alone or in combination with immunotherapy targeting the cell surface protein(s).

The disclosure provides synthetic peptides that selectively bind to the PD-L1 protein on the surface of cells expressing PD-L1. The PD-L1 binding peptide may comprises the amino acid sequence MX1X2X3X4DHX5LNKFX6IX7HXsX9X10X11X12X13 (SEQ ID NO: 177) or MXIFπXXIXXXΩWXLXXA (SEQ ID NO: 1). Peptides of the disclosure may be functionalized using one or more diagnostic agents to aid in various detection modalities or with a cytotoxic agent to treat various disease states such as cancer. Also provided are compositions that include the PD-L1 binding peptides or functionalized PD-L1 binding peptides.

Methods of killing cells are described. In particular examples, the method includes contacting a cell having a cell surface protein with a therapeutically effective amount of an antibody-IR700 molecule, wherein the antibody specifically binds to the cell surface protein, such as a tumor-specific antigen on the surface of a tumor cell. The cell is subsequently irradiated, such as at a wavelength of 660 to 740 nm at a dose of at least 1 J cm−2. The cell is also contacted with one or more therapeutic agents (such as an anti-cancer agent), for example about 0 to 8 hours after irradiating the cell, thereby killing the cell. Also provided are methods of imaging cell killing in real time, using fluorescence lifetime imaging.

The present disclosure relates to heterobifunctional molecules, referred to as cytotoxicity targeting chimeras (CyTaCs) or antibody recruiting molecules (ARMs) that are able to simultaneously bind a target cell-surface protein as well as an exogenous antibody protein. The present disclosure also relates to agents capable of binding to a receptor on a surface of a pathogenic cell and inducing the depletion of the pathogenic cell in a subject for use in the treatment of cancer, inflammatory diseases, autoimmune diseases, viral infection, or bacterial infection.